Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by E. Brain
Real-world analysis of patients’ clinical and geriatric characteristics aged ≥70 years with advanced breast cancer receiving palbociclib with endocrine therapy in the French cohort PALOMAGE
Background: Due to the common exclusion of older patients with cancer from clinical trials, few specific data are available on the treatment of advanced breast cancer (ABC) in this population.
First line hormone therapy vs chemotherapy for HR+ HER2- metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count
Background: In patients (pts) diagnosed with HR+ HER2- metastatic BC the choice between by front-line hormone therapy (HT, favored option) or chemotherapy (CT) is based on prognostic factors that are overpassed by CTC count. The STIC CTC trial is a large multicentric phase III randomized trial comparing two strategies to choose the front-line treatment type: decision by clinician vs by CTC levels.
Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study
Background Bevacizumab combined with paclitaxel as first-line chemotherapy for patients with HER2-negative metastatic breast cancer (MBC) has led to mixed results in randomized trials, with an improvement in progression-free survival (PFS) but no statistically significant overall survival (OS) benefit. Real-life data could help in assessing the value of this combination.
Paclitaxel plus Bevacizumab or Paclitaxel as First-line Treatment for HER2-Negative Metastatic Breast Cancer in a Multicenter National Observational Study
Background Bevacizumab combined with paclitaxel as first-line chemotherapy for patients with HER2-negative metastatic breast cancer (MBC) has led to mixed results in randomized trials, with an improvement in progression-free survival (PFS) but no statistically significant overall survival (OS) benefit. Real-life data could help in assessing the value of this combination.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with E.
Contact E., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack